Trial Profile
A Phase 1 Study of CNTO 888, a Human Monoclonal Antibody Against CC-Chemokine Ligand 2 in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2010
Price :
$35
*
At a glance
- Drugs Carlumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Oct 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 21 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2010 Actual patient number (44) added as reported by ClinicalTrials.gov.